Company: BLRX
Filing Date: 2025-03-31
Form Type: 20-F
Source: 0001178913-25-001123
Chunk: 348

Company: BioLineRx Ltd.
Filing Date: 2025-03-31
Form: 20-F
Item: Item 19
Chunk 348
---
, primarily related to its main drug candidate, AGI-134 (see Note 1a). In December 2023, the Company made a decisio...
$ 15.0 million associated with BL-8040 were recorded following an amendment to the in-licensing agreement with Biokine Therapeutics Ltd. (“ Biokine”). This amendment reduced the payments owed b...
Set forth below are the composition of intangible assets and the related accumulated depreciation, grouped by major classifications:
Composition in 2023
Intellectual property 21,792 450 21,342 96 6,703 6,799 14,543
Computer software 801 - 982 612 - 671 311
22,593 450 22,324 708 6,703 7,470 14,854
Composition in 2024
Intellectual property 21,342 3,323 18,019 6,799 1,010 7,809 14,543
Computer software 982 - 798 671 - 559 311
22,324 3,323 18,817 7,470 1,010 8,368 14,854

F - 29

BioLineRx Ltd.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

NOTE 10 - LEASES
Right-of-use assets
Cost Accumulated depreciation
Balance at Additions Deletions Balance at Net book value
beginning during during beginning December 31,
of year year year of year 2023
in USD thousands in USD thousands in USD thousands
Composition in 2024
Property 2,097 239
Motor vehicles 368 88
2,465 327
Lease liabilities
Balance at Additions Deletions Interest expense
beginning during during during
of year year year year
of year year year year
───────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
in USD thousands
Composition in 2024
Property 1,556 239 208
Motor vehicles 262 88 32
1,818 327 240
Additional disclosures
The Company leases two premises - its corporate headquarters and development facilities in Modi’in, Israel, and its U. S. commercial headquarters in Waltham, Massachusetts.
────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
The Company